Effect of neoadjuvant chemotherapy on low-density lipoprotein (LDL) receptor and LDL receptor-related protein 1 (LRP-1) receptor in locally advanced breast cancer

Imagem de Miniatura
Arquivos
art_PIRES_Effect_of_neoadjuvant_chemotherapy_on_low_density_lipoprotein_2012.PDF (4.16 MB)
Citações na Scopus
45
Tipo de produção
article
Data de publicação
2012
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ASSOC BRAS DIVULG CIENTIFICA
Autores
Citação
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, v.45, n.6, p.557-564, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Low-density lipoprotein (LDL) receptors are overexpressed in most neoplastic cell lines and provide a mechanism for the internalization and concentration of drug-laden nanoemulsions that bind to these receptors. The aim of the present study was to determine whether the administration of standard chemotherapeutic schemes can alter the expression of LDL and LDL receptor-related protein 1 (LRP-1) receptors in breast carcinoma. Fragments of tumoral and normal breast tissue from 16 consecutive volunteer women with breast cancer in stage II or III were obtained from biopsies before the beginning of neoadjuvant chemotherapy and after chemotherapy, from fragments excised during mastectomy. Tissues were analyzed by immunohistochemistry for both receptors. Because complete response to treatment was achieved in 4 patients, only the tumors from 12 were analyzed. Before chemotherapy, there was overexpression of LDL receptor in the tumoral tissue compared to normal breast tissue in 8 of these patients. LRP-1 receptor overexpression was observed in tumors of 4 patients. After chemotherapy, expression of both receptors decreased in the tumors of 6 patients, increased in 4 and was unchanged in 2. Nonetheless, even when chemotherapy reduced receptors expression, the expression was still above normal. The fact that chemotherapy does not impair LDL receptors expression supports the use of drug carrier systems that target neoplastic cells by the LDL receptor endocytic pathway in patients on conventional chemotherapy.
Palavras-chave
Breast cancer, Lipoproteins, LDL receptor, LRP-1 receptor, Chemotherapy, Nanoemulsion, Drug delivery
URI
https://observatorio.fm.usp.br/handle/OPI/811
Referências
  1. Ades A, 2001, GYNECOL ONCOL, V82, P84, DOI 10.1006/gyno.2001.6203
  2. Azevedo CHM, 2005, GYNECOL ONCOL, V97, P178, DOI 10.1016/j.ygyno.2004.12.015
  3. Brown M. S., 1991, CURR OPIN LIPIDOL, V2, P65, DOI 10.1097/00041433-199104000-00002
  4. deVries TJ, 1996, CANCER RES, V56, P1432
  5. Dias MLN, 2007, CANCER CHEMOTH PHARM, V59, P105, DOI 10.1007/s00280-006-0252-3
  6. FRIEDEWA.WT, 1972, CLIN CHEM, V18, P499
  7. GAL D, 1981, INT J CANCER, V28, P315, DOI 10.1002/ijc.2910280310
  8. GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0
  9. Graziani SR, 2002, GYNECOL ONCOL, V85, P493, DOI 10.1006/gyno.2002.6654
  10. HENRIKSSON P, 1989, LANCET, V2, P1178
  11. Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI13992
  12. HO YK, 1978, BLOOD, V52, P1099
  13. Hungria VTM, 2004, CANCER CHEMOTH PHARM, V53, P51, DOI 10.1007/s00280-003-0692-y
  14. IWANIK MJ, 1984, CANCER RES, V44, P1206
  15. KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810
  16. Lo Prete AC, 2006, J PHARM PHARMACOL, V58, P801, DOI 10.1211/jpp.58.6.0010
  17. LUNDBERG B, 1987, CANCER RES, V47, P4105
  18. Maranhao RC, 2002, CANCER CHEMOTH PHARM, V49, P487, DOI 10.1007/s00280-002-0437-3
  19. MARANHAO RC, 1993, LIPIDS, V28, P691, DOI 10.1007/BF02535988
  20. MARANHAO RC, 1994, CANCER RES, V54, P4660
  21. MASQUELIER M, 1986, CANCER RES, V46, P3842
  22. Mendes S, 2009, GYNECOL ONCOL, V112, P400, DOI 10.1016/j.ygyno.2008.10.018
  23. MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892
  24. OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
  25. Pinheiro KV, 2006, CANCER CHEMOTH PHARM, V57, P624, DOI 10.1007/s00280-005-0090-8
  26. Pires L, 2009, CANCER CHEMOTH PHARM, V63, P281, DOI 10.1007/s00280-008-0738-2
  27. Rodrigues DG, 2005, CANCER CHEMOTH PHARM, V55, P565, DOI 10.1007/s00280-004-0930-y
  28. RUDLING MJ, 1986, BRIT MED J, V292, P580
  29. RUDLING MJ, 1983, CANCER RES, V43, P4600
  30. STRICKLAND DK, 1995, FASEB J, V9, P890
  31. Teixeira LC, 2000, TRATADO GINECOLOGIA, V3, P2019
  32. Teixeira RS, 2004, J PHARM PHARMACOL, V56, P909, DOI 10.1211/0022357023826
  33. Teixeira RS, 2008, J PHARM PHARMACOL, V60, P1287, DOI 10.1211/jpp/60.10.0004
  34. VITOLS S, 1992, CANCER RES, V52, P6244
  35. Yamamoto M, 1997, CANCER RES, V57, P2799
  36. [Anonymous], 2010, AJCC CANC STAG MAN

Coleções
Artigos e Materiais de Revistas Científicas - FM/MOG
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/31
Artigos e Materiais de Revistas Científicas - LIM/58